San Diego-based GlySens says it has raised $12 million in Series C funding to advance its wireless technology for an implantable sensor that could be used to monitor blood sugar levels in people with diabetes.
No investors were identified in the statement issued by GlySens, which says only that several new investors participated in the round, along with a group of existing investors.
Though diabetes treatment and prevention have improved in recent years, EU member states are too slow when it comes to proper implementation and monitoring of policies. This means that Europe is losing the battle against the growing diabetes epidemic, according to a new study.
It’s been a big year for Intarcia Therapeutics. The Boston- and Hayward, CA-based firm raised a massive round of private financing for its experimental drug/device combo treatment for Type 2 diabetes, and then followed that up with some encouraging data in late-stage clinical trials. Now, with that product, ITCA 650, potentially just a few years from the market, Intarcia has found a large pharmaceutical company to help sell it overseas in a deal that could be worth more than $1 billion.
There’s an oft-heard story in digital health circles: A patient comes into the doctor’s office complaining of common pre-diabetic symptoms, so the doctor — who has no treatment code for “pre-diabetes” — tells the patient, “Come back when you have diabetes.”
And the patient often does come back with diabetes.
Les Centers for Disease Control and Prevention (CDC) viennent de publier une étude encourageante sur l'évolution du diabète aux Etats-Unis [1]. En effet, alors que le nombre de diabétiques n'a cessé de croître depuis des décennies, le taux d'apparition de nouveaux cas de diabètes semble enfin diminuer. Néanmoins, les efforts doivent continuer afin de lutter efficacement contre cette épidémie.
Investing now in diabetes prevention will reduce the cost of tackling the disease later and maintain a productive European workforce, experts claim.
As more people in Europe become overweight or obese due to unhealthy diets and sedentary lifestyles, more people will also get diabetes.
The World Health Organisation (WHO) estimates that between 36.9 and 56.7% of women aged 15-74 in the EU are obese, while the same figures for men are between 51% and 69.3%, depending on the country.
Promoted as an aid to good health, artificial sweeteners may in fact be boosting diabetes risk, said an Israeli study Wednesday that urged a rethink of their widespread use and endorsement.
Also called non-calorific artificial sweeteners, or NAS, the additives are found in diet sodas, cereals and desserts — a huge market for people worried about weight gain and sugar intake.
Some experts recommend NAS for people with Type 2 diabetes, a disease that has attained pandemic proportions, and for a pre-diabetic condition called glucose intolerance, with elevated blood-sugar levels.
On Wednesday (17 September), the Health Consumer Powerhouse (HCP), a Swedish company which compares healthcare between countries, will reveal an analysis of diabetes prevention and treatment in Europe, making it easier for EU member states to share best practices.
At the Congress of the European Association for the Study of Diabetes (EASD) in Vienna, HCP will publish an index which covers 28 defined indicators and areas, including Prevention, Case finding, Range and reach of services, Access to treatment and care, Procedures and Outcomes. After putting the indicators in a scoreboard up against the 30 European countries analysed, the HCP will rank the countries according to how they meet the indicator requirements.
L'Université de Colombie-Britannique (UBC), en collaboration avec BetaLogics Venture, un département de Janssen Research & Development, LLC, a publié une étude mettant en évidence un protocole pour convertir des cellules souches en cellules productrices d'insuline. La nouvelle procédure pourrait être une étape importante dans la lutte contre le diabète de type 1.
